glp 1 picture Glucagon-like peptide-1 The Latest on GLP-1s |

Modern GLP-1 receptor agonists have demonstrated average weight loss of 15-20% of body weight with sustained treatment, representing a breakthrough in obesity pharmacotherapy that approaches the effectiveness of bariatric surgery

Beginning July 1, 2026, eligible Medicare beneficiaries can access four GLP-1 weight-loss medications through the temporary Medicare GLP-1 Bridge Program: Wegovy injections, Wegovy tablets, Zepbound KwikPen, and Foundayo

Kaynaka World Health Organization

Are foreign pharmacies advertising in your local newspaper

Advertising Standards Authority

An explosion in the use of the GLP-1s like Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound has subsequently resulted in an overabundance of used needles